New radioactive tracers could spot cancers more clearly
NCT ID NCT07639970
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is to see if the tracers are safe and can help doctors see tumors more clearly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radioactive tracers (68Ga-HT547 and 177Lu-HT547)
What this could lead to
If successful, this could lead to a more accurate way to detect and monitor certain solid tumors using imaging scans.
What could go wrong
This is a very early, small study (20 people) focused on safety and imaging, not treatment. It may not lead to better outcomes for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••